8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet
43
Participants partenaires
TERMINÉ
Educational Network in Ocular Drug Delivery and Therapeutics (OcuTher)
Date du début: 1 nov. 2016, Date de fin: 31 oct. 2020,
Ocular drug development has transformed from niche area to a major field in drug development in which many companies, including European big pharma has entered recently. Ocular drug development is a unique field in terms of drug targets and end-points of activity, local drug administration routes, tissue barriers and pharmacokinetics, drug delivery and formulation challenges and local toxicity iss ...
Voir le projet
9
Participants partenaires
TERMINÉ
Oral biopharmaceutics tools (ORBITO)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,
The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet
28
Participants partenaires
TERMINÉ
Treatment of Adrenal Insufficiency in neonates- Development of a Hydrocortisone Preparation for the treatment of Adrenal Insufficiency in neonatesand infants (TAIN)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2016,
The aim of TAIN is to develop a neonatal formulation of hydrocortisone, a drug included in the EMA priority list that needs specific evaluation in the age range 0 – 2 years (neonates & infants). Hydrocortisone is an essential glucocorticoid hormone used as replacement therapy for the treatment of congenital and acquired adrenal insufficiency as well playing an important therapeutic role in oncolog ...
Voir le projet
8
Participants partenaires
TERMINÉ
Drug Disease Model Resources (DDMORE)
Date du début: 1 mars 2011, Date de fin: 31 août 2016,
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capa ...
Voir le projet
28
Participants partenaires
TERMINÉ
Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
"The aim of TINN2 is to evaluate azithromycin, included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. Azithromycin is a macrolid antibiotic with anti-inflammatory properties active against Ureaplasma. It might be effective in reducing the severity of bronhopulmonary disease in which Ureaplasma infection and inflammation play a r ...
Voir le projet
17
Participants partenaires
TERMINÉ
Neuroscience on Barriers in Development (NEUROBID)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2013,
"Brain diseases are one of the most prevalent groups of diseases in Europe with estimated annual costs amounting to €386 billion (1). Data collected by the WHO suggest that brain diseases are responsible for 35% of Europe’s total disease burden (1). In the treatment of neurological disease, the blood brain barrier (BBB) still represents an obstacle for the delivery of drugs to the brain and thus a ...
Voir le projet
10
Participants partenaires
TERMINÉ
Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics (Predict-IV)
Date du début: 1 mai 2008, Date de fin: 31 oct. 2013,
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early develo ...
Voir le projet